KB-1194

MGD007-GPA33-hIgG1

Background

GPA33 antigen is uniformly and highly expressed in colorectal cancer, with abundant GPA33 binding sites present in every cell. This suggests that GPA33 may be a potential therapeutic target for colon cancer. The high expression level of GPA33 antigen and the presence of numerous binding sites make it an ideal treatment target. In recent years, research has been ongoing regarding the role of GPA33 antibody in colorectal cancer, and it has been demonstrated that GPA33 antibody can effectively kill GPA33-positive tumor cells. This indicates the potential of GPA33 antibody in treating colon cancer. Further research and development of this potential therapeutic target are expected in clinical settings. Through additional experiments and clinical trials, the efficacy and safety of GPA33 antibody in treating colorectal cancer can be evaluated. If the study results are positive, GPA33 antibody has the potential to become a new treatment method for colon cancer.

Specifications

Catalog Number:
KB-1194
Cell Line Name:
MGD007-GPA33-hIgG1
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GPA33
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Moore P A, Shah K, Yang Y, et al. Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer[J]. Molecular Cancer Therapeutics, 2018, 17(8): 1761-1772. 2.Wu Z, Guo H F, Xu H, et al. Development of a tetravalent Anti-GPA33/Anti-CD3 bispecific antibody for colorectal cancers[J]. Molecular cancer therapeutics, 2018, 17(10): 2164-2175. 3.Cheal S M, Xu H, Guo H, et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86 Y-or 177 Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates[J]. European journal of nuclear medicine and molecular imaging, 2016, 43: 925-937.
Please enable JavaScript in your browser to complete this form.